Abstract
BackgroundSMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 2) is an important ATPase catalytic subunit in the switch-sucrose nonfermenting (SWI/SNF) complex. However, its relationship with the pathological features of NSCLC and its prognosis remain unclear.MethodsWe retrospectively reviewed 2390 patients with surgically resected NSCLC, constructed tissue microarrays (TMAs) and performed immunohistochemical assays. We analyzed the correlation of SAMRCA2 with clinicopathological features and evaluated its prognostic value.ResultsAmong 2390 NSCLC cases, the negative expression ratios of SAMRCA2, SMARCA4, ARID1A, ARID1B and INI1 were 9.3%, 1.8%, 1.2%, 0.4% and 0%, respectively. In NSCLC, male sex, T3 and T4 stage, moderate and poor differentiation, tumor ≥ 2 cm, Ki67 ≥ 15%, SOX-2 negative expression, middle lobe lesion and adenocarcinoma were relative risk factors affecting SMARCA2-negative expression. In lung adenocarcinomas, high-grade nuclei, histological morphology of acinar and papillary, solid and micropapillary and TTF-1-negative expression were relative risk factors affecting SMARCA2-negative expression. Kaplan–Meier survival analysis showed that the OS was shorter in the SMARCA2-negative group. Multivariate survival analysis revealed that SMARCA2-negative expression was an independent factor correlated with a poor prognosis in NSCLC.ConclusionIn conclusion, SMARCA2-negative expression is an independent predictor of a poor outcome of NSCLC and is a potential target for NSCLC treatment.
Highlights
According to Global Cancer Statistics 2020, lung cancer is the second most common malignancy among new cancer cases worldwide (11.4% of all new cases), and it remains the “leading cause” of cancer death (18.0% of all cancer deaths) [1]
3.1.2 Positive staining of the switch-sucrose nonfermenting (SWI/SNF) subunits was localized in the nucleus, while no nuclear staining was observed in Non-small-cell Lung Cancer (NSCLC) cells with SWI/SNF subunit deletion, and as an internal control, the nuclei of infiltrating lymphocytes or bronchial epithelial cells in the same section were positive (Fig. 1)
The results showed that SWI/SNF Related (SMARCA2)-negative expression, age > 60 years, III and IV pathological stage, pleural invasion, spread through air spaces (STAS), Ki67 2 15%, and lymphatic metastasis were independent prognostic factors associated with shorter Overall survival (OS) (Fig. 3 A, B)
Summary
According to Global Cancer Statistics 2020, lung cancer is the second most common malignancy among new cancer cases worldwide (11.4% of all new cases), and it remains the “leading cause” of cancer death (18.0% of all cancer deaths) [1]. In China, lung cancer is the most common malignant tumor, with the highest morbidity and mortality from cancer in all populations [2]. In NSCLC, male sex, T3 and T4 stage, moderate and poor differentiation, tumor 2 2 cm, Ki67 2 15%, SOX-2 negative expression, middle lobe lesion and adenocarcinoma were relative risk factors affecting SMARCA2negative expression. High-grade nuclei, histological morphology of acinar and papillary, solid and micropapillary and TTF-1-negative expression were relative risk factors affecting SMARCA2-negative expression. Multivariate survival analysis revealed that SMARCA2-negative expression was an independent factor correlated with a poor prognosis in NSCLC. Conclusion: In conclusion, SMARCA2-negative expression is an independent predictor of a poor outcome of NSCLC and is a potential target for NSCLC treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
